The review found that irinotecan with platinum may be associated with higher overall response and survival rates than etoposide with platinum for previously untreated extensive-stage small cell lung cancer, with a differing side-effect profile. The authors suggested that their findings required cautious interpretation: this appears justified in view of the heterogeneity, small number and questionable quality of the primary studies.
IP was associated with significantly lower rates of anaemia (OR 0.51, 95% CI 0.36 to 0.72; six RCTs), neutropenia (OR 0.26, 95% CI 0.12 to 0.54; six RCTs) and thrombocytopenia (OR 0.29, 95% CI 0.20 to 0.41; six RCTs). IP was associated with significantly higher rates of vomiting (OR 1.51, 95% CI 1.01 to 2.25; five RCTs) and diarrhoea (OR 10.52, 95% CI 5.94 to 18.65; six RCTs). There was no significant difference between the groups in treatment-related mortality (four RCTs).
There was significant heterogeneity in the analyses of overall survival (I 2 =67%), progression-free survival (I 2 =79%) and neutropaenia (I 2 =84%). No evidence of significant publication bias was found. Subgroup analyses restricted to studies that used cisplatin found no significant difference between the groups for efficacy outcomes.
Authors' conclusions
IP may be associated with higher overall response and survival rates than EP in individuals with previously untreated extensive-stage small cell lung cancer, with a differing side-effect profile.
CRD commentary
The objectives and inclusion criteria of the review were clear. Relevant sources were searched for studies. There were no restrictions by language and publication status. Appropriate tests were used to assess for publication bias. Steps were taken to minimise risks of reviewer bias and error by having more than one reviewer undertake validity assessment and data extraction; it was unclear whether this also applied to study selection.
Overall study quality appeared to be poor, but no details were reported and study quality was hardly mentioned in the interpretation of results. Appropriate statistical techniques were used to combine the studies and assess for heterogeneity. There was significant heterogeneity for some outcomes, which the authors suggested might relate to differences in participant ethnicity and in the type and dose-intensity of the drugs used.
